New study aims to uncover hidden danger in kawasaki disease
NCT ID NCT07491926
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will observe 150 children with Kawasaki disease to learn more about a rare but serious complication called Macrophage Activation Syndrome (MAS). Researchers will collect data on symptoms, lab results, and treatments across multiple European hospitals. The goal is to better understand how often MAS occurs, what puts children at risk, and how to diagnose it more accurately.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better ways to identify and treat MAS in children with Kawasaki disease, potentially preventing serious complications.
What could go wrong
This is an observational study, not a treatment trial. It may not directly change care, and results depend on accurate diagnosis and data collection across many hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAWASAKI DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliero-Universitaria IRCCS Meyer
Florence, Italy, 50139, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••